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Background
Asthma management guidelines suggest little difference
between EF and SP-ICS other than potency and there-
fore EF-ICS should be used at same dose as fluticasone
(FP) and half the dose of SP-beclomethasone (BDP).
Cohort studies suggest EF-BDP patients can achieve bet-
ter asthma control than FP patients at lower doses. We
compared baseline characteristics and first prescribed
doses of patients initiating ciclesonide vs. SP-ICS.
Methods
Data from the PHARMO Database Network (pharmacy
and hospital discharge records) on patients (12-60 years
old) with ≥2 prescriptions for asthma therapy (2005-
2012) were compared over 1 year before initiating cicle-
sonide vs SP-ICS. Co-morbidities were evaluated over
1 year before and after ICS initiation. To avoid inclusion
of potential COPD patients, those >60 years old and
those using long-acting muscarinic antagonists were
excluded. Sex and age at ICS initiation; initial ICS doses
(actual prescribed doses); short-acting b2-agonists (SABA)
use (year before initiation); prescriptions for acute oral
steroids and overall asthma control (no hospital admis-
sions, no acute oral steroids and ≤200mcg/day salbutamol)
in the year prior and including initiation date; and pre-
scriptions of drugs for treating co-morbidities (year before
and after initiation) were compared using t-test/chi-square
test (p<0.05).
Results
Of 4,064 patients, 34% initiated therapy as ciclesonide
and 66% as SP-ICS, with same proportion of males
(36%). Differences (p<0.001, unless otherwise specified)
for ciclesonide vs. SP-ICS were: mean(±SD) age (43±13
vs. 38±14 years); median(Inter Quartile Range) initial
ICS doses 160(160-160) vs. 500(250-500) μg; proportion
of patients not on SABA (72% vs. 57%) and on SABA
daily dosage between 1-100 μg/day (21% vs. 29%), 101-
200 μg/day (5% vs. 9%) and >200 μg/day (2% vs. 6%);
proportion of patients not prescribed acute oral steroids
(90% vs. 88%, p=0.016) and with controlled asthma (87%
vs. 82%); proportion of patients prescribed nasal (44%
vs. 38%) and topical (31% vs. 28%) steroid preparations,
proton-pump inhibitors (41% vs. 29%) and cardiac dis-
eases or hypertension drugs (28% vs. 21%).
Conclusions
For comparable asthma control and similar prevalence
of co-morbidities, patients were prescribed triple the
dose of SP-ICS versus ciclesonide. Further to this analy-
sis, the effects on asthma control in the year following
ICS initiation will be investigated.
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